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Introduction
In addition to its participation in growth factor regulation of 
proliferation and apoptosis, the extracellular signal–regulated 
kinase (ERK)–MAPK pathway has important functions in the 
differentiation of postmitotic cells. For example, in Xenopus 
laevis embryos, inhibition of ERK activation prevents animal 
caps from differentiating into mesenchymal tissue (Umbhauer 
et al., 1995), whereas mice harboring deletions in ERK2 exhibit 
severe defects in primary mesenchyme formation without major 
changes in cell proliferation or apoptosis (Yao et al., 2003). 
In addition, this pathway can regulate the activity of several 
 lineage-specifi  c transcription factors, including MyoD (muscle; 
Zetser et al., 2001), Sox9 (cartilage; Murakami et al., 2000, 
2004), and PPARγ (adipose tissue; Adams et al., 1997). In bone, 
the ERK–MAPK pathway is a major conduit for conveying 
  information about the extracellular environment to the nucleus, 
and has been implicated in the response of bone to a variety of 
signals, including hormone/growth factor stimulation (Hurley 
et al., 1996; Xiao et al., 2002b; Chen et al., 2004), extracellular 
matrix–integrin binding (Takeuchi et al., 1997; Xiao et al., 
2002a), and mechanical loading (You et al., 2001).
Despite intensive investigation, the physiological role of 
the MAPK pathway in osteoblasts remains controversial, with 
some studies supporting a stimulatory role in osteoblast differ-
entiation and others proposing that this pathway is inhibitory 
(for review see Schindeler and Little, 2006). For example, acti-
vation of α2β1 integrins by the type I collagen matrix of bone 
was reported to stimulate in vitro osteoblast differentiation via 
focal adhesion kinase activation of MAPK (Takeuchi et al., 
1997; Xiao et al., 1998). Also, short-term pharmacological inhi-
bition of MAPK signaling blocked osteoblast-specifi  c gene ex-
pression in mature osteoblasts, whereas a constitutively active 
form of the MAPK intermediate, MEK1, was stimulatory (Xiao 
et al., 2002a). In related studies, we showed that RUNX2, which 
is an essential transcription factor for bone formation (Ducy 
et al., 1997), is required for cells to respond to MAPK in vitro. 
Both phosphorylation and transcriptional activity of RUNX2 
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T
he extracellular signal–regulated kinase (ERK)–
  mitogen-activated protein kinase (MAPK) pathway 
provides a major link between the cell surface and 
nucleus to control proliferation and differentiation. How-
ever, its in vivo role in skeletal development is unknown. 
A transgenic approach was used to establish a role for 
this pathway in bone. MAPK stimulation achieved by 
  selective expression of constitutively active MAPK/ERK1 
(MEK-SP) in osteoblasts accelerated in vitro differentia-
tion of calvarial cells, as well as in vivo bone develop-
ment, whereas dominant-negative MEK1 was inhibitory. 
The involvement of the RUNX2 transcription factor in 
this response was established in two ways: (a) RUNX2 
phosphorylation and transcriptional activity were ele-
vated in calvarial osteoblasts from TgMek-sp mice and 
reduced in cells from TgMek-dn mice, and (b) crossing 
TgMek-sp mice with Runx2+/− animals partially res-
cued the hypomorphic clavicles and undemineralized 
calvaria associated with Runx2 haploinsufﬁ  ciency, 
whereas TgMek-dn; Runx2+/− mice had a more severe 
skeletal phenotype. This work establishes an important 
in  vivo function for the ERK–MAPK pathway in bone 
that involves stimulation of RUNX2 phosphorylation and 
transcriptional activity.
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were stimulated by the ERK–MAPK pathway, suggesting that 
this factor is a MAPK substrate and an important mediator of 
the MAPK response (Xiao et al., 2000; Franceschi et al., 2003). 
Also, treatment of MC3T3-E1 cells or primary cultures of mar-
row stromal cells with FGF2 induced RUNX2 phosphorylation 
and osteocalcin expression by a process requiring MAPK acti-
vation (Xiao et al., 2002b). In contrast, other in vitro studies 
reached an opposite conclusion, showing that the ERK–MAPK 
pathway can antagonize osteoblast functions. Thus, epidermal 
growth factor stimulation of ERK prevented SMAD1 activation 
by bone morphogenetic proteins in epithelial cells (Kretzschmar 
et al., 1997). This inhibition was explained by ERK-dependent 
phosphorylation of a distinct site in the linker region of SMAD1 
that led to the exclusion of this molecule from the nucleus 
(Kretzschmar et al., 1999). Also, chronic treatment of osteoblast 
cultures with MAPK inhibitors was reported to actually stimu-
late osteoblast differentiation, whereas ERK activation was 
  inhibitory (Higuchi et al., 2002; Nakayama et al., 2003).
The confl  icting results of in vitro studies emphasize the 
need to address the role of the ERK–MAPK pathway in osteo-
blast function in vivo. To this end, a unique transgenic strategy 
was developed involving selective expression of constitutively 
active and dominant-negative forms of the MAPK intermediate 
MEK1 in osteoblasts using the osteocalcin promoter. With this 
approach, ERK–MAPK activation was found to stimulate osteo-
blast differentiation and skeletal development through a pathway 
involving RUNX2.
Results
Generation of transgenic mice
Transgenic mice were developed using a 647-bp mouse osteo-
calcin (Ocn) gene 2 (mOG2) promoter to drive osteoblast-specifi  c 
expression of constitutively active (MEK-SP) or dominant-
  negative (MEK-DN) forms of the MAPK intermediate MEK1 
(Wu et al., 1996; Sugimoto et al., 1998). Ocn transcription is low 
in proliferating osteoprogenitor cells, and it does not become 
elevated until the later stages of differentiation, when cells are 
largely postmitotic (Owen et al., 1990; Xiao et al., 1997). By us-
ing a promoter that is selectively expressed in postmitotic cells, 
we reasoned that it should be possible to target MAPK functions 
related to osteoblast differentiation, rather than earlier functions 
associated with cell proliferation. A schematic representation of 
the transgene construct is shown in Fig. 1 a. This mOG2 promoter 
region contains suffi  cient information to selectively express a 
lac Z reporter in osteoblasts with no detectable expression in 
cartilage or joints (Frendo et al., 1998). A total of fi  ve transgenic 
founders were obtained for each construct. Of these, three lines 
having approximately equivalent transgene expression were 
retained for further study. Mice were viable and bred normally. 
As shown in Fig. 1 (b and c), strong transgene expression was 
detected in skeletal tissues, fi  rst appearing at E14.5 and per-
sisting in newborn animals. No transgene expression was seen in 
soft tissues, such as muscle, brain, or liver (unpublished data). 
Similar expression levels and tissue distribution were seen with 
all lines examined. For this reason, subsequent experiments used 
lines SP221 and DN288, with certain experiments repeated with 
SP413 and DN315. In situ hybridization conducted in newborn 
mice showed clear localization of the transgene to osteoblasts 
on endosteal and select trabecular surfaces of long bones and the 
conspicuous absence of expression in growth plates (Fig. 1 d). 
Similar localization to osteoblast layers of the calvarium was 
also observed (unpublished data).
Transgenic modiﬁ  cation of MAPK activity 
alters in vitro osteoblast differentiation
Initial studies examined the effects of transgene expression on 
the in vitro growth and the differentiation of calvarial osteo-
blasts. Cells were isolated from 4-wk-old wild-type, TgMek-sp, 
and -dn mice and grown under differentiating conditions. Trans-
gene expression was fi  rst detected after 7 d in culture, and con-
tinued to increase throughout the experiment (Fig. 2 a). Western 
blotting with a specifi  c anti–phospho-ERK antibody was used 
to verify that transgenes altered ERK–MAPK signaling (Fig. 2 b). 
Figure 1.  Development of transgenic mouse lines over-
expressing constitutively active and dominant-negative 
MEK1 in osteoblasts. (a) Schematic representation of a 
transgene construct. A −647 to +13 bp fragment of the 
murine mOG2 promoter was used to drive expression 
of constitutively active (MEK-SP) and dominant-negative 
MEK1 mutants in osteoblasts. (b) Tissue distribution of 
transgene expression. Total RNA was isolated from the in-
dicated tissues of 4-wk-old mice, and transgene expression 
measured by RT-PCR. The lines used, from left to right, 
were as follows: DN288, DN388, DN315, SP413, 
SP221, and SP211. GAPDH mRNA levels are shown as a 
control for RNA loading. Transgene expression was not 
detected in muscle, brain, or liver (not depicted). (c) Trans-
gene expression time course during embryonic devel-
opment. Results with SP221 and DN288 are shown. 
(d) Distribution of transgene expression in long bone. In situ 
hybridization was used to localize transgene mRNA to 
endosteal and select trabecular surfaces of a newborn 
TgMek-dn femur (line DN288). (top) Hematoxylin and 
  eosin–stained section; middle, in situ hybridization with 
  digoxigenin-labeled sense probe; bottom, antisense probe. 
Inset, 2× magniﬁ  cation of boxed area. Bar, 250 μm.MAP KINASE REGULATION OF BONE DEVELOPMENT • GE ET AL. 711
TgMek-sp cells had phospho-ERK levels that were nearly twice 
those of their wild-type littermates, whereas phospho-ERK in 
TgMek-dn cells was reduced by 50%. In contrast, total ERK 
levels were not affected by transgene expression. To confi  rm 
that the increased phospho-ERK levels in TgMek-sp cells are 
explained by constitutive activation of MEK, cells were treated 
with the Raf inhibitor ZM336372, which blocks the MAPK 
pathway upstream of MEK1/2 (Hall-Jackson et al., 1999). As 
expected, this inhibitor dramatically reduced phospho-ERK 
levels in cells from wild-type and TgMek-dn mice, while having 
no effect on levels in TgMek-sp cells.
As a component in growth factor signaling, the ERK–
MAPK pathway can stimulate cell proliferation (Stokoe et al., 
1994). However, growth curves for wild-type, TgMek-sp, and 
TgMek-dn cells were identical, with all groups growing to the 
same saturation density (Fig. 2 c). This is likely explained by 
the delayed expression of transgenes from the mOG2 promoter 
that does not become active until culture day 7, when cells are 
close to confl  uence and largely postmitotic (compare Figs. 2, 
a and c). This late transgene expression facilitated the interpreta-
tion of subsequent experiments by removing proliferation and 
cell density as possible confounding variables.
In contrast to the results of proliferation studies, Mek-dn 
and -sp transgenes dramatically altered calvarial cell differ-
entiation and gene expression (Fig. 2, d–j). Differentiation of 
  TgMek-dn cells was reduced relative to wild type, as measured 
by von Kossa staining of mineralized nodules at day 14 (Fig. 
2 d), alkaline phosphatase activity (Fig. 2 e), calcium accu-
mulation as mineral (Fig. 2 f) and expression of OCN, bone 
sialo protein  (BSP), and alkaline phosphatase (ALP) mRNAs 
(Fig. 2, g–i). Time course studies revealed that the earliest effects 
of transgenes were seen at day 10, immediately after initial 
transgene expression was detected at day 7 (Fig. 2 a). Runx2 
mRNA was not affected at day 7, but was reduced by 40% on 
day 10 and 14. Opposite results were obtained with TgMek-sp 
cells that accumulated twice the mineral of wild-type cells at d 
14 and had higher levels of alkaline phosphatase and osteoblast 
marker mRNAs. Runx2 mRNA levels were only slightly stimu-
lated on days 10 and 14.
RUNX2 phosphorylation 
and transcriptional activity
The Ocn, Bsp, Akp2 (ALP), and Runx2 genes shown to be regu-
lated by Mek-sp and -dn in Fig. 2, g–h are all known to be 
Figure 2.  Altered osteoblast differentiation in 
calvarial cells from TgMek-dn and -sp mice. 
Cells were isolated from calvaria of newborn 
wild-type and transgenic animals. (a) Time 
course of transgene expression. Cells were 
plated and grown in differentiating medium for 
the indicated times before measurement of 
transgene mRNA by RT-PCR. (b) Mek-dn and -sp 
transgene expression alters ERK phosphorylation. 
Cells were grown as in a and harvested after 
10 d for measurement of total and phospho-ERK 
by Western blotting. The indicated groups 
were treated with the Raf inhibitor ZM336372 
2 h before harvest. (c) Transgene expression 
does not alter cell growth. (d–j) MEK-DN in-
hibits, whereas MEK-SP stimulates, osteoblast 
differentiation. The following differentiation mark-
ers were measured: mineralized nodules in 14-d 
cultures (d), alkaline phosphatase activity (e), 
total cell layer–associated, acid-extractable 
calcium (f), and OCN, BSP, ALP, and Runx2 
mRNA levels (g–j; all   measured by real-time 
RT-PCR). Values are the mean ± the SD of trip-
licate independent samples.JCB • VOLUME 176 • NUMBER 5 • 2007  712
  directly or indirectly controlled by RUNX2. For Ocn, Bsp, and 
Runx2 itself, this regulation involves direct binding of RUNX2 
to regulatory elements in the proximal promoter region (Ducy 
et al., 1997; Tou et al., 2003; Roca et al., 2005). In previous 
cell culture studies, we showed that MAPK activation by either 
transient transfection of the MC3T3-E1 osteoblast cell line 
with a MEK-SP expression vector or activation of endogenous 
ERK phosphorylation by treatment with FGF2 stimulated phos-
phorylation and transcriptional activity of RUNX2 (Xiao et al., 
2000, 2002b).
Two types of experiments were conducted to determine if 
RUNX2 phosphorylation and transcriptional activity is modi-
fi  ed in cells from TgMek-sp and -dn mice, and if changes in 
phosphorylation could explain differences in osteoblast differ-
entiation. In the fi  rst experiment, cells were grown under differ-
entiating conditions for 7 d and metabolically labeled with 
[
32P]orthophosphate, and then total RUNX2 was immuno-
precipitated from cell extracts using a specifi  c polyclonal anti-
body. A replicate culture was labeled with [
35S]Met/Cys and 
processed in the same way to normalize 
32P incorporation to 
 total RUNX2. As shown in Fig. 3 (a and b), steady-state RUNX2 
phosphorylation was increased twofold in TgMek-sp cells ver-
sus wild-type controls, while phosphorylation in TgMek-dn 
cells was reduced by 50%. In the second study, cells were trans-
fected with 1.3-kb mOG2-luc or 6OSE2-luc reporter genes, and 
luciferase activity was measured after 3 and 7 d. A previous 
work showed that both of these promoter constructs are highly 
responsive to RUNX2 (Ducy et al., 1997). The 1.3-mOG2 frag-
ments, like 0.647-kb mOG2, contains all known elements 
  necessary for osteoblast-specifi  c expression of Ocn, including 
RUNX2 binding sites (osteoblast-specifi  c element 2 [OSE2]) at 
−608 and 137, whereas 6OSE2-luc contains six copies of the 
OSE2 site in front of a minimal mOG2 promoter (from −47 to 
13 bp; Ducy and Karsenty, 1995; Yang et al., 2004). After 7 d in 
culture, luciferase activity from both reporter genes was higher in 
TgMek-sp cells than wild-type cells, whereas activity in TgMek-dn 
cells was reduced (Fig. 3, c and d). In contrast, no differences in 
activity were seen at day 3, which is before Mek-sp and -dn trans-
genes become active.
These results cannot be explained by differences in total 
RUNX2 levels or overall cell differentiation that were un affected 
by transgenic status at the 7-d time point (Fig. 2, e–j). Rather, 
the ability of RUNX2 to stimulate OSE2-dependent transcrip-
tional activity was increased. Collectively, these studies show 
that modest perturbations in ERK–MAPK activity via trans-
genic expression of MEK-SP or -DN in postmitotic osteoblasts 
dramatically affect in vitro RUNX2 phosphorylation, RUNX2-
dependent transcriptional activity, and osteoblast  differentiation. 
Changes in RUNX2 activity preceded differentiation changes, 
which is consistent with the concept that Mek-dependent regu-
lation of this transcription factor accounts, at least in part, for 
subsequent changes in differentiation.
TgMek-sp and -dn alter skeletal development
Consistent with results obtained in osteoblast cultures, skeletal 
development was accelerated in TgMek-sp and delayed in 
  TgMek-dn embryos (Fig. 4). This was refl  ected by differences 
in skeletal size, body weight, and mineralization. Skeletons 
from TgMek-sp embryos were signifi  cantly larger (based on fe-
mur lengths at embryonic day (E) 15.5 [Fig. 4, c and f] and body 
weight [Fig. 4, a and d]) than wild-type littermates, and weights 
and embryo size were reduced in TgMek-dn mice. Moreover, 
differences in calvarial mineralization were apparent with min-
eralized area of calvarial preparations at E15.5 being reduced 
by 20% in TgMek-dn and stimulated by an equivalent amount 
in TgMek-sp embryos (Fig. 4, b and e).
Striking differences in skeletal maturation of long bones 
were also seen when histological sections of E15.5 embryos 
were examined (Fig. 5 a). At this age, the initial stages of endo-
chondral bone formation have normally already taken place, 
Figure 3.  Changes in RUNX2 phosphorylation and transcriptional activity 
in osteoblasts from TgMek-dn and -sp mice. (a and b) Regulation of 
RUNX2 phosphorylation. Calvarial cells were grown under differentiating 
conditions for 7 d before metabolic labeling with [
32P]orthophosphate or 
[
35S]methionine/cysteine (to normalize for total RUNX2) and immunoprecip-
itation with an anti-Runx2 antibody. Each IP reaction contained 500 μg total 
protein. (b) Normalized 
32P incorporation into RUNX2. (c and d) Runx2-
  dependent transcriptional activity. Cells were transfected with p1.3mOG2-
luc (c) or p6OSE2mOG2-luc (d) plasmids and grown under differentiating 
conditions for the times indicated before measurement of   luciferase activity. 
Values are the means ± the SD of triplicate independent samples.MAP KINASE REGULATION OF BONE DEVELOPMENT • GE ET AL. 713
with vascular invasion and metaphyseal bone formation already 
well underway (Komori et al., 1997). However, this process was 
signifi  cantly delayed in TgMek-dn embryos. Only early bone 
collar formation was apparent, with cartilage still occupying 
the inner metaphyseal regions of all long bones examined. In 
contrast, TgMek-sp embryos exhibited accelerated   trabecular 
bone formation, with the metaphyseal region already having 
expanded toward the diaphyses. These results indicate that 
ERK–MAPK activity is important for the early stages of intra-
membraneous and endochondral bone development.
Interaction between Mek-sp and -dn 
transgenes and Runx2
The cell culture studies shown in Fig. 3, as well as previous work 
from this laboratory (Xiao et al., 2000), suggest that RUNX2 is 
an important target for regulation by the ERK–MAPK pathway 
in osteoblasts. To test this concept in vivo, we examined ge-
netic interactions between Runx2 and Mek-sp or -dn transgenes. 
Runx2+/− mice are known to phenocopy many aspects of the 
human genetic disease cleidocranial dysplasia (CCD), including 
the characteristic clavicular hypoplasia and open fontanelles 
of the cranium with lesser involvement of other skeletal sites 
(Otto et al., 1997). Because clavicles and cranial bones are par-
ticularly sensitive to the effects of Runx2 haploinsuffi  ciency, we 
predicted that these two tissues should be preferentially sen-
sitive to transgenic modifi  cation of the ERK–MAPK pathway 
under conditions where RUNX2 is limiting.
TgMek-sp or -dn mice were crossed with Runx2+/− 
mice, and skeletal phenotypes were determined using whole-
mount skeletal preparations (Fig. 5). Fig. 5 (a–d) show the anal-
ysis of E18.5 animals from TgMek-sp x Runx2+/− breedings, 
and Fig. 5 (e–h) show results of the TgMek-dn x Runx2+/− 
cross. Runx2+/− mice exhibited the expected clavicular hyper-
trophy and calvarial hypomineralization of CCD, with a resul-
tant reduction of clavicle cross-sectional area of 75 (Fig. 5, 
c and g), and 28, and 18%, respectively, in mineralized areas of 
calvaria (Fig. 5, d and h). In contrast, femur length was not 
 signifi  cantly affected (Fig. 5, b and f).
Figure 4.  Altered skeletal development in 
  TgMek-dn and -sp mice. (a) Whole mounts of 
E15.5 skeletons stained with alcian blue and 
alizarin red. (d) Effects of transgene expression 
on embryo weights. (b and e) Cranial bones 
showing differences in mineralization (b) and 
quantiﬁ  cation of mineralized area (expressed 
as the percentage of total calvarial area; e). 
(c and f) Hindlimbs showing differences in the 
size of bones with transgene expression (c) 
and quantiﬁ  cation of femur lengths (f). (g) His-
tology of long bones from wild-type, TgMek-
dn, and -sp mice. Note delay in bony collar 
and trabecular bone in TgMek-dn embryos. 
Statistical analysis values are expressed as the 
mean ± the SD. n = 8 mice/group. *, signiﬁ  -
cantly different from wild type at P < 0.01.JCB • VOLUME 176 • NUMBER 5 • 2007  714
The Mek-sp transgene was able to partially rescue both 
the clavicular hypertrophy and calvarial hypomineralization 
of Runx+/− mice. Transgene expression increased the cross-
sectional area of clavicles by 53% in Runx2+/− animals, 
  although it only increased this parameter by 12% in wild-
type mice (Fig. 5, c). Restoration of calvarial mineralization 
was also observed with TgMek-sp, increasing this parameter 
in Runx2+/− animals to 90% of the wild-type control (a 23% 
increase relative to Runx2+/− mice; Fig. 5, d). In contrast, 
Mek-sp had no effect on femur length in Runx2+/− mice, 
but it did increase this parameter by 18% in wild-type litter-
mates (Fig. 5, b).
Results with the TgMek-dn x Runx2+/− cross were even 
more striking. First, after four consecutive breedings, we failed 
to obtain viable newborn pups with the TgMek-dn;Runx2+/− 
genotype. This is in contrast to the TgMek-sp;Runx2+/− 
  genotype that was present in the expected Mendelian ratio. 
When embryos were harvested by Caesarean section at E18.5, 
TgMek-dn;Runx2+/− embryos were obtained in the expected 
ratios, indicating that this genotype cannot survive the birth 
Figure 5.  Genetic interactions between Mek-dn and -sp transgenes and Runx2. TgMek-dn or -sp mice were crossed with Runx2+/− mice to generate the 
genotypes indicated. (a–d) Partial rescue of CCD phenotype in Runx2+/− mice with Mek-sp. (a) Skeletal whole mounts of newborn mice stained with 
alcian blue and alizarin red (top), isolated clavicles (middle), and crania (bottom). (b–d) measurements of femur length (b), clavicle areas (c), and mineralized 
area of calvaria (expressed as a fraction of total calvarial area). (e–h) Increased severity of CCD phenotype with Mek-dn. Groups are as in a–d. Statistical 
analysis values are expressed as the means ± the SD. n = 8 mice/group. Comparisons are indicated by bars. *, signiﬁ  cantly different at P < 0.01.MAP KINASE REGULATION OF BONE DEVELOPMENT • GE ET AL. 715
  process. Embryos were smaller and exhibited selective worsening 
of CCD-associated features. Specifically, Mek-dn reduced 
  clavicular cross-sectional area by 67% in Runx+/− embryos, 
but only reduced this value by 17% in Runx+/+ mice (Fig. 5, g). 
Also, Mek-dn reduced calvarial mineralization by 31% in 
Runx2+/− embryos, but only reduced this value by 15% in 
wild type (Fig. 5, h). Collectively, these results show that 
in Runx2+/− mice, the clavicles, and calvaria are selectively 
sensitive to manipulation of ERK–MAPK activity in osteo-
blasts, which is consistent with the concept that RUNX2 is an 
in vivo target of this pathway.
Discussion
In this study, we show that the ERK–MAPK pathway can posi-
tively regulate bone development in vivo through a mechanism 
involving RUNX2. Phosphorylation and transcriptional activity 
of RUNX2 were stimulated in calvarial osteoblasts from 
Tg Mek-sp mice and inhibited in TgMek-dn cells. Furthermore, 
Runx2 haploinsuffi  ciency selectively enhanced the effects of 
Mek-sp and -dn transgenes on clavicles and calvaria, two tis-
sues known to be preferentially sensitive to Runx2 gene dosage. 
On the basis of this work, we conclude that ERK–MAPK sig-
naling is critical for in vivo osteoblast activity, and propose that 
this response is explained, at least in part, by phosphorylation 
and activation of RUNX2.
These results are consistent with previous cell culture 
studies from this and other laboratories. For example, we re-
ported that MAPK activation, either by transfection of osteo-
blasts with constitutively active MEK1 or treatment with FGF2, 
rapidly increased RUNX2 phosphorylation and transcriptional 
activity through a process that was blocked by MAPK inhibi-
tion, whereas acute inhibition of MAPK in differentiated cells 
blocked osteoblast-specifi  c gene expression (Xiao et al., 2000, 
2002a,b). In related studies, Lai et al. (2001) showed that ex-
pression of a dominant-negative ERK1 blocked differentiation 
of human osteoblasts. Similarly, differentiation of human mar-
row stromal cells to osteoblasts is accompanied by sustained 
ERK1/2 phosphorylation; pharmacological MAPK inhibition 
or dominant-negative ERK blocked osteoblast formation in this 
system and stimulated adipogenesis (Jaiswal et al., 2000). Also, 
several reports support our hypothesis that MAPK actions in 
osteoblasts are, at least in part, mediated by RUNX2. During 
osteoblast differentiation of human marrow stromal cells, 
RUNX2 type II levels remain relatively unchanged, but binding 
to OSE2 DNA increased, as did RUNX2 phosphorylation (Shui 
et al., 2003). Also, mechanical loading of osteoblasts, which is 
known to be mediated, in part, through integrin activation, in-
duces MAPK (Pavalko et al., 1998; Schmidt et al., 1998); loading 
of periodontal ligament cells (which are osteoprogenitor-like 
cells associated with tooth cementum) increased RUNX2 phos-
phorylation and binding to OSE2 DNA via an ERK–MAPK-
dependent process (Ziros et al., 2002). In osteoblast-like prostate 
cancer cells, differentiation is accompanied by ERK1/2 activation, 
increased RUNX2-OSE2 binding, and Ocn expression, responses 
that are all blocked by MAPK inhibition (Zayzafoon et al., 
2004). Lastly, IGF-1, which activates P13K and, sub  sequently, 
the ERK–MAPK pathway, stimulates RUNX2-OSE2 binding 
and phosphorylation in vascular endothelial cells (Qiao et al., 
2004), as well as differentiation of marrow stromal cells (Celil 
and Campbell, 2005; Celil et al., 2005).
This work is to be contrasted with other in vitro studies 
that reported antagonism between the ERK–MAPK pathway 
and BMPs in epithelial cells (Kretzschmar et al., 1997, 1999) 
and inhibitory effects of this pathway on osteoblast differentiation 
(Higuchi et al., 2002; Nakayama et al., 2003; Schindeler and 
Little, 2006). Possible explanations for these disparate results 
may be related to differences in the magnitude and duration of 
MAPK activation and/or stage of cell maturation that are both 
known to affect MAPK responsiveness. For example, treatment 
of PC12 neuronal progenitor cells with EGF transiently stimu-
lated ERK1/2 phosphorylation and cell proliferation, whereas 
NGF led to sustained ERK activation and neuronal differentia-
tion, a result explained by the formation of transient versus 
long-lived complexes of MAPK-activating factors (Kao et al., 
2001). Similarly, in studies with MC3T3-E1 preosteoblasts, 
EGF suppressed BMP-dependent Smad 1 activation, whereas 
sustained ERK–MAPK activation by extracellular   matrix 
  synthesis or constitutively active Ras stimulated BMP activity 
(Suzawa et al., 2002). In contrast, the aforementioned studies, 
indicating an inhibitory role for MAPK in osteoblast differenti-
ation, generally either treated cells with MAPK inhibitors for 
extended times or stably transfected cells with expression vec-
tors that produced high levels of constitutively active or domi-
nant-negative MAPK intermediates during all stages of growth 
and differentiation.
To examine the in vivo actions of the ERK–MAPK path-
way in osteoblasts, this study used the mOG2 promoter to drive 
expression of constitutively active/dominant-negative MEK1 in 
developing mice. Because this promoter is only active in mature 
osteoblasts that are largely postmitotic (Owen et al., 1990), we 
were able to discriminate between effects of MAPK on cell pro-
liferation versus differentiation. Furthermore, transgenic modi-
fi  cation led to sustained, but quite modest, changes in ERK1/2 
phosphorylation ( 50% increased/decreased levels). Using 
this approach, ERK–MAPK activation was shown to stimulate 
  osteoblast differentiation of calvarial osteoblasts from trans-
genic animals and to accelerate bone accumulation in develop-
ing embryos without affecting cell proliferation. In contrast, 
dominant-negative MAPK inhibition slowed osteoblast differ-
entiation in cell culture and delayed bone development. In vivo 
effects of transgenes were most striking in calvaria and long 
bones. Of particular interest, long bones of TgMek-dn mice dis-
played   delayed bone collar formation, whereas TgMek-sp was 
associated with an increase in metaphyseal bone without any 
obvious effects on cartilage. This is consistent with an in situ 
analysis of transgene expression that was unable to detect trans-
gene expression in growth plates (Fig. 1).
In agreement with our in vitro studies, we also obtained 
evidence that MAPK regulates RUNX2 transcriptional activity. 
Calvarial osteoblasts from transgenic mice exhibited the pre-
dicted changes in RUNX2 phosphorylation and transcriptional 
activity, with these parameters being stimulated in TgMek-sp 
cells and inhibited with Mek-dn. Of note, changes in RUNX2 JCB • VOLUME 176 • NUMBER 5 • 2007  716
were coincident with initial activation of Mek-sp and -dn trans-
genes and preceded any changes in osteoblast differentiation 
markers or RUNX2 mRNA that were all equivalent in wild-
type, TgMek-sp, and -dn groups at the 7-d time point examined 
(Figs. 2 and 3). Thus, it is unlikely that changes in RUNX2 
phosphorylation/activity are secondary to changes in osteoblast 
differentiation induced by Mek-sp/dn transgenes. Studies that 
examined genetic interactions between Runx2 and Mek-sp 
and -dn transgenes provided further evidence for in vivo regula-
tion of RUNX2 by MAPK (Fig. 5). Because clavicles and cal-
varia are preferentially sensitive to Runx2 haploinsuffi  ciency, 
they are good markers for changes in RUNX2 transcriptional 
  activity. The observation that TgMek-sp is able to rescue the 
CCD phenotype of Runx2+/− embryos, whereas TgMek-dn 
exacerbated clavicular and calvarial defects provides compel-
ling in vivo evidence for our hypothesis that the ERK–MAPK 
pathway regulates RUNX2.
Studies in other differentiating systems, such as muscle, 
fat, and cartilage, suggest that the ERK–MAPK pathway, act-
ing through tissue-specifi  c transcription factors, may generally 
control progenitor/stem cell lineage decisions in mesenchymal 
tissues. For example, in X. laevis muscle differentiation, MAPK 
increases levels of XMyoD, possibly by decreasing protein 
turnover (Zetser et al., 2001). In fat, phosphorylation of PPARγ 
by ERK1 inhibits transcriptional activity of this factor to block 
adipogenesis (Adams et al., 1997). Lastly, MAPK activation by 
FGFs, constitutively active FGFR3, or MEK1 mutants in carti-
lage increases levels of Sox9 to keep chondrocytes in a pre-
hypertrophic state (Murakami et al., 2000, 2004).
Studies in cartilage are of particular interest in that they 
used the Col2a1 promoter to express the same constitutively ac-
tive MEK1 mutant used in this study. In contrast to our results 
with osteoblasts, Col2a1-mediated expression led to a chondro-
dysplasia phenotype that is characterized by shortened limbs 
and inhibition of hypertrophy without affecting chondrocyte 
proliferation. The observed limb shortening was explained by a 
reduction in the size of chondrocytes in the hypertrophic zone. 
Because the ERK–MAPK pathway is known to activate Sox9 
(Murakami et al., 2000), the authors postulated that this tran-
scription factor prevents hypertrophy, which normally requires 
Sox9 down-regulation. In contrast, our use of the mOG2 pro-
moter to express constitutively active MEK1 resulted in expres-
sion in osteoblasts rather than cartilage, acceleration of bone 
development and skeletal mineralization, and no obvious changes 
in cartilage. As was the case for stimulation of Sox9 in cartilage, 
we fi   nd that ERK–MAPK can activate RUNX2-dependent 
transcriptional activity in osteoblasts.
Although our studies focused on RUNX2 as the primary 
mediator of MAPK signals, other transcription factors may also 
participate in this response, functioning together with RUNX2 
to control gene expression. Of primary interest, ERK is known 
to phosphorylate and activate a second kinase, RSK2, in the 
  cytoplasm of many cells (Fisher and Blenis, 1996). RSK2 
phosphorylates ATF4, a transcription factor that, together with 
RUNX2, controls the osteoblast-specifi  c expression of the 
  osteocalcin gene (Yang et al., 2004). Mice defi  cient in either 
RSK2 or ATF4 have similar bone phenotypes characterized by 
delayed cranial and long-bone development (Yang et al., 2004). 
Furthermore, RUNX2 and ATF4 physically and functionally 
interact in osteoblasts, although it is not known whether 
phosphorylation of RUNX2 and/or ATF4 affects this inter-
action (Xiao et al., 2005). While this work was under review, 
Elefteriou et al. (2006) reported that the high bone-mass phenotype 
of mice harboring an osteoblast-specifi  c deletion of the Ras GT-
Pase-activating protein (GAP), Nf1, involves activation of the 
ERK–MAPK pathway. Although these authors attributed the 
phenotype of Nf1−/− mice exclusively to activation of ATF4 
via RSK2, the involvement of Runx2 was not directly exam-
ined. To address the possible involvement of ATF4 in TgMek-sp 
and -dn mice, we transfected calvarial osteoblasts with an ATF4 
reporter-luciferase construct containing oligomerized copies 
of the ATF4-responsive enhancer OSE1 (Ducy and Karsenty, 
1995; Yang et al., 2004). Unlike results with the RUNX2 
  reporters (Fig. 3), this construct was not affected by transgene 
activity (not depicted). Based on this result, the involvement of 
ATF4 in the osteogenic response seen with transgenic ERK–
MAPK activation appears to be secondary to that of RUNX2. 
However, this issue still needs to be examined in greater detail.
This study establishes an important role for the ERK–
MAPK pathway in RUNX2 regulation, osteoblast differentia-
tion, and fetal bone development. Furthermore, the animal 
models developed will be extremely useful for assessing roles 
of ERK–MAPK signaling during bone remodeling in adult and 
ageing mice, as well as for evaluating the possible therapeutic 
value of MAPK manipulation as a means of regulating bone 
mass in diseased states.
Materials and methods
Generation of transgenic mice
The plasmid pGL647 contains a region of the mOG2 gene from −647 to 
+13 bp, which was previously shown to contain sufﬁ  cient information to 
drive osteoblast-speciﬁ  c gene expression in vivo (Frendo et al., 1998). Two 
mutated forms of MEK1 cDNA were individually subcloned into pGL647. 
MEK(SP) includes S218/222E mutations and deletion of residues 32–51 
to produce a constitutively active MEK1 mutant (Sugimoto et al., 1998), 
whereas the dominant-negative mutant MEK(DN) contains S218/222A 
mutations (Wu et al., 1996). Plasmids were linearized by digestion with 
ClaI, and DNA fragments for microinjection were puriﬁ   ed using a 
  Nucleospin Extraction kit (CLONTECH Laboratories, Inc.). Transgene 
  constructs are quantiﬁ  ed and microinjected into (C57BL/6 X SJL) F2 mouse 
oocytes (Charles River Laboratories) and surgically transferred to pseudo-
pregnant C57BL/6 dams. The founders were screened by PCR using 
mouse tail genomic DNA. Transgenic expression in tissues was assessed 
by RT-PCR using two sets of transgene-speciﬁ  c primers. Primers used for 
MEK(SP) were 5′-C  G  G  A  G  A  C  C  A  A  C  T  T  G  G  A  G  G  C  -3′ and 5′-C  G  A  A  T  T  C  G  T  T-
G  G  C  C  A  T  T  T  C  -3′; primers used for MEK(DN) were 5′-C  G  G  A  G  A  C  C  A  A  C  T  T-
G  G  A  G  G  C  -3′ and 5′-C  G  A  A  G  G  C  G  T  T  G  G  C  C  A  T  G  G  C  -3’. The last six 
nucleic acids in the ends of downstream primers harbored mutations 
that were used to discriminate between transgene and endogeneous MEK1 
expression. Transgenic founder animals were bred into C57BL/6 mice for 
at least six generations to obtain a deﬁ  ned genetic background. Previously 
described heterozygous Runx2+/− mice (Otto et al., 1997) were ob-
tained from P. Ducy (Baylor College of Medicine, Houston, TX). All studies 
with mice were performed in compliance with the University of Michigan 
Committee for the Use and Care of Animals.
Histological examination and in situ hybridization
Tissues were ﬁ  xed in 10% formalin and embedded in parafﬁ  n, and 7-μm-
thick sections were cut and stained with hematoxylin and eosin. RNA in situ 
hybridization was done using a digoxigenin-labeled riboprobe speciﬁ  c for 
SV40 sequences in the transgene (Roche). Sections were viewed with a MAP KINASE REGULATION OF BONE DEVELOPMENT • GE ET AL. 717
microscope (Eclipse 50i; Nikon) using a 10× objective. Images were cap-
tured with a digital camera (Stereo TLRC; Leica) using Image-Pro Plus 5.1 
(Media Cybernetics) acquisition software without further manipulation.
Whole-mount skeletal preparations
Skeletal morphology was analyzed by alizarin red and alcian blue stain-
ing, followed by tissue clariﬁ   cation with KOH, as previously described 
(Yang et al., 2004). To measure bone length, isolated bones were laid next 
to a ruler and photographed using a digital camera and stereo dissection 
scope. Bone area was calculated using ImagePro Plus software.
Cell culture and Western blot analysis
Primary calvarial osteoblasts were isolated from 4-wk-old transgenic mice 
and littermates, as previously described (Ducy and Karsenty, 1995). Cells 
were grown in α-MEM/10% FCS until conﬂ  uent. Cells were then replated 
at a density of 5 × 10
3 cells/cm
2 in 35-mm dishes and grown for up to 
2 wk in differentiation medium (α-MEM, 10% FCS, 50 μg/ml ascorbic 
acid, and 5 mM β-glycerol phosphate). Quantitative RT-PCR was performed 
using an ABI PRISM 7700 Sequence Detection System. Optimized primers 
and probes for Ocn,  Bsp,  Akp2,  Runx2, and Gapdh were purchased 
from Applied Biosystems. Total and phospho-ERK1/2 were measured on 
Western blots using speciﬁ   c antibodies at a dilution of 1:2,000 (Cell 
Signaling Technology).
Cell transfections and metabolic labeling
Primary calvaria osteoblasts were isolated from newborn mice and cul-
tured in 75-cm ﬂ  asks for 3 d until conﬂ  uent. Cells were then trypsinized and 
replated on 35-mm dishes at a density of 2.5 × 10
5 cells/cm
2. After 24 h, 
cells were transfected with Fugene6 (Roche) according to the manufacturer’s 
instructions. Each transfection contained 0.5 μg of p1.3mOG2-luc or 
p6OSE2-luc (Ducy and Karsenty, 1995) and 0.05 μg of pRL-SV40 
(encodes Renilla reformis luciferase to control for transfection efﬁ  ciency). Cells 
were then cultured in differentation medium for an additional 6 d before 
harvesting and assaying for luciferase activity using a Dual Luciferase 
Assay kit (Promega) on a luminometer (Monolight 2010; BD Biosciences).
For cell labeling, calvarial cells were cultured for 6 d, as described 
in the previous paragraph, and transferred to phosphate or cysteine and 
methionine-free medium containing 0.1% dialyzed FCS (Sigma-Aldrich). 
After an overnight preincubation, cells were labeled for 5 h in the 
same media containing either 150 μCi/ml of [
32P]orthophosphate or 
[
35S]cysteine/methionine (MP Biomedical). Preparation of nuclear extracts 
and immunoprecipitation of Runx2 were described previously (Xiao et al., 
2000). 
32P/
35S incorporation was measured using an A2024 Instant-
Imager (Packard).
Statistical analysis
Statistical analyses were performed using Instat 3.0 (GraphPAD Software, 
Inc.). For cell culture studies (Figs. 2 and 3), values are the means ± the SD 
of triplicate independent samples. In studies with mice, n = 8 mice/group. 
Analysis of variance followed by Tukey-Kramer multiple comparisons test 
was used to assess signiﬁ  cance between groups as indicated.
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